Despite advances, HIV stigma and misunderstanding remain, GSK and ViiV study showsnews2021-12-31T16:34:22+00:00December 31st, 2021|Fierce Pharma|
Xeris Biopharma scores FDA approval for endogenous Cushing’s syndrome drug Recorlevnews2021-12-30T22:26:37+00:00December 30th, 2021|Fierce Pharma|
Teva suffers trial loss in New York’s landmark opioid casenews2021-12-30T19:51:48+00:00December 30th, 2021|Fierce Pharma|
To buy or not to buy? Samsung unit denies report about Biogen talksnews2021-12-30T13:13:59+00:00December 30th, 2021|Fierce Pharma|
Don’t spam us, healthcare professionals plea, as they seek quality over quantity from pharma marketersnews2021-12-29T22:29:49+00:00December 29th, 2021|Fierce Pharma|
Biogen’s rollercoaster 2021 takes another surprising turn with report of $42B Samsung buyout interestnews2021-12-29T20:13:19+00:00December 29th, 2021|Fierce Pharma|
Biogen’s roller coaster 2021 takes another surprising turn with report of $42B Samsung buyout interestnews2021-12-29T20:13:19+00:00December 29th, 2021|Fierce Pharma|
Bristol Myers Squibb, Amgen and Pfizer approach steepest patent cliffs among large drugmakersnews2021-12-29T15:04:33+00:00December 29th, 2021|Fierce Pharma|
Leo Pharma gains FDA nod for eczema drug Adbry, but can it challenge Sanofi and Regeneron’s formidable Dupixent?news2021-12-28T16:09:28+00:00December 28th, 2021|Fierce Pharma|
Merck, Ridgeback clinch FDA’s 2nd emergency nod for a COVID-19 antiviral pillnews2021-12-27T14:39:36+00:00December 27th, 2021|Fierce Pharma|
